Status:
COMPLETED
Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms
Lead Sponsor:
Columbia Northwest Pharmaceuticals
Conditions:
Major Depressive Disorder
Dysthymia
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The investigators hypothesize that patients receiving citalopram in combination with lithium will have a greater reduction in depressive symptoms than patients receiving citalopram in combination with...
Eligibility Criteria
Inclusion
- 18-75 years of age
- Meets criteria for Major Depressive Disorder, Dysthymia, Depression Not Otherwise Specified or Borderline Personality Disorder
- Ability to speak, read and understand the English Language and provide written informed consent
Exclusion
- Current, unstable and significant medical condition or illness
- History of Thyroid disorder, seizure disorder, tumors or other CNS condition that predisposes the patient to risk of seizure
- Pregnant or lactating females
- Abnormal clinical laboratory test results
- Intolerance or hypersensitivity to SSRIs or lithium
- History or current diagnosis of bipolar mood disorder, psychosis, schizophrenia or dementia
- Certain mediations my not be used prior or during the study
Key Trial Info
Start Date :
March 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT01189812
Start Date
March 1 2010
End Date
January 1 2011
Last Update
August 24 2011
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Artemis Institute for Clinical Research
San Diego, California, United States, 92123
2
Northwest Clinical Research Center
Bellevue, Washington, United States, 98007